OverviewSuggest Edit

SWK Holdings Corporation is a specialized finance company focused on the global healthcare sector. It operates in two segments: Finance Receivables and Pharmaceutical Development. The Finance Receivables segment offers customized financing solutions to life science companies, institutions, and inventors. The Pharmaceutical Development segment comprises Enteris BioPharma, a clinical stage biopharmaceutical company offering formulation solutions built around its proprietary oral drug delivery technologies, the Peptelligence platform.

TypePublic
Founded1996
HQDallas, TX, US
Websiteswkhold.com

Latest Updates

Employees (est.) (Dec 2019)30
Revenue (FY, 2020)$36.7 M(+20%)
Share Price (Dec 2021)$19.6
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at SWK Holdings

Winston Black

Winston Black

Chairman and Chief Executive Officer
Charles Jacobson

Charles Jacobson

Chief Financial Officer
Jody Staggs

Jody Staggs

Managing Director
Yvette Heinrichson

Yvette Heinrichson

Controller
Brannon Morisoli

Brannon Morisoli

Director
Show more

SWK Holdings Office Locations

SWK Holdings has an office in Dallas
Dallas, TX, US (HQ)
14755 Preston Rd #105
Show all (1)

SWK Holdings Financials and Metrics

SWK Holdings Revenue

SWK Holdings's revenue was reported to be $36.71 m in FY, 2020
USD

Revenue (Q1, 2021)

9.4m

Net income (Q1, 2021)

3.4m

Market capitalization (31-Dec-2021)

253.1m

Closing stock price (31-Dec-2021)

19.6

Cash (31-Mar-2021)

1.6m

EV

273.8m
SWK Holdings's current market capitalization is $253.1 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

637.0k6.4m17.4m23.5m22.4m37.5m26.0m30.7m36.7m

General and administrative expense

1.5m2.2m1.7m3.3m3.4m2.8m4.1m4.9m7.4m10.5m

R&D expense

1.2m4.3m

Operating expense total

1.5m2.2m1.7m3.3m3.4m2.8m4.1m4.9m8.6m14.8m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Revenue

54.0k430.0k1.0m1.6m3.7m3.4m3.7m5.8m5.4m5.7m5.2m8.6m4.2m14.9m6.1m5.5m6.8m6.8m5.9m9.4m5.7m6.3m7.3m7.9m9.4m

General and administrative expense

311.0k364.0k300.0k711.0k846.0k390.0k424.0k463.0k669.0k742.0k1.1m1.2m945.0k460.0k929.0k789.0k617.0k661.0k951.0k1.5m1.2m1.2m1.3m1.3m1.3m2.7m3.0m2.6m2.9m

R&D expense

286.0k1.2m1.0m1.5m

Operating expense total

311.0k364.0k300.0k711.0k846.0k390.0k424.0k463.0k669.0k742.0k1.1m1.2m945.0k460.0k929.0k789.0k617.0k661.0k951.0k1.5m1.2m1.2m1.3m1.3m1.3m3.6m4.2m4.7m5.6m
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

38.2m24.6m7.7m58.7m47.3m32.2m30.6m20.2m11.2m3.0m

Accounts Receivable

197.0k528.0k1.1m1.1m1.1m1.6m2.2m2.6m1.9m

Prepaid Expenses

66.0k36.0k16.0k19.0k720.0k126.0k637.0k336.0k1.3m

Current Assets

38.3m26.0m9.0m71.1m16.6m6.7m
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(1.1m)(1.4m)14.3m23.6m(4.4m)32.0m8.3m6.2m23.8m5.2m

Depreciation and Amortization

2.0k5.0k2.0k3.0k10.0k5.0m19.3m

Accounts Payable

(14.0k)(94.0k)234.0k498.0k(76.0k)(106.0k)1.2m(1.3m)1.7m1.5m

Cash From Operating Activities

(1.2m)(1.1m)1.3m5.1m11.2m9.6m19.5m19.6m18.5m19.3m
USDQ2, 2011

Financial Leverage

1 x
Show all financial metrics

SWK Holdings Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

30-39

out of 100

CSRHub logo

SWK Holdings Online and Social Media Presence

Embed Graph

SWK Holdings News and Updates

SWK Holdings Announces Strategic Plan to Focus on Core Specialty Finance Business

DALLAS, Nov. 1, 2021 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small and mid-sized commercial-stage companies, today provided an update on the results of the Strategic Review Committee's...

EyePoint Pharmaceuticals Announces $16.5 Million Monetization of ILUVIEN® Royalty with SWK Holdings Corporation

WATERTOWN, Mass., Dec. 18, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious eye disorders, today announced a royalty monetization a…

SWK Holdings Corporation to Participate in A.G.P.'s Virtual Healthcare Symposium

DALLAS, Nov. 11, 2020 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH), a life science focused specialty finance company, today announced that its chairman and chief executive officer, Winston Black, will participate in A.G.P.'s Virtual Healthcare Symposium on Thursday, November...

SWK Holdings to Participate in 2020 Colliers Institutional Investor Conference

DALLAS, Sept. 9, 2020 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH), a life science focused specialty finance company, today announced that its chairman and chief executive officer, Winston Black, will participate in the 2020 Colliers Institutional Investor Conference, taking...

SWK Holdings Corporation Announces Reauthorization of Share Repurchase Program and Provides Business Update on Coronavirus (COVID-19) Impact

DALLAS, March 26, 2020 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small and mid-sized commercial-stage companies, today announced its preliminary revenue and non-GAAP adjusted net income for the fourth quarter and...

SWK Holdings to Present at the Fall Investor Summit

DALLAS, Sept. 16, 2019 /PRNewswire/ -- SWK Holdings Corporation (SWKH.OB) ("SWK" or the "Company"), a life science focused specialty finance company, announced that CEO Winston Black will present at the Fall Investor Summit being held today in New York City. Details of SWK's presentation...
Show more

SWK Holdings Blogs

Enteris BioPharma Highlights 2021 Achievements and 2022 Outlook

Enteris continues to capitalize on multiple value building opportunities involving Peptelligence® and ProPerma® platforms

Biotricity Completes $12 Million Non-Dilutive Debt Financing

Capital infusion to finance inventory and annual recurring revenue subscriptions replaces expiring debt with more favorable terms

Demystifying the Covenant Setting Process

At SWK, we believe that financial covenants and the process of setting mutually agreeable covenant levels play an important role in the lender/borrower relationship. A lender’s willingness to engage in the discussions and accommodate the requests outlined herein can be.. Read More » The post Demysti…
Show more

SWK Holdings Frequently Asked Questions

  • When was SWK Holdings founded?

    SWK Holdings was founded in 1996.

  • Who are SWK Holdings key executives?

    SWK Holdings's key executives are Winston Black, Charles Jacobson and Jody Staggs.

  • How many employees does SWK Holdings have?

    SWK Holdings has 30 employees.

  • What is SWK Holdings revenue?

    Latest SWK Holdings annual revenue is $36.7 m.

  • What is SWK Holdings revenue per employee?

    Latest SWK Holdings revenue per employee is $1.2 m.

  • Who are SWK Holdings competitors?

    Competitors of SWK Holdings include Grupo Nc, Teva and Takeda.

  • Where is SWK Holdings headquarters?

    SWK Holdings headquarters is located at 14755 Preston Rd #105, Dallas.

  • Where are SWK Holdings offices?

    SWK Holdings has an office in Dallas.

  • How many offices does SWK Holdings have?

    SWK Holdings has 1 office.